Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) is dated October 16, 2019. The report addresses preliminary financial results for the quarter ended September 30, 2019, and significant amendments to the company's debt and equity agreements with Innovatus Life Sciences Lending Fund I, LP.
Key Financial Metrics
- Revenue: The company estimates total revenue for the three months ended September 30, 2019, to be $3.3 million. This figure is unaudited and preliminary.
- Profit, Cash Flow, and Margins: The filing text does not provide clear values for net income, operating cash flow, or profit margins.
- Debt and Liquidity: The company failed to meet minimum revenue targets and minimum cash balance covenants under its Loan and Security Agreement dated March 14, 2019.
Material Changes and Covenant Waivers
The company did not achieve the minimum revenue covenant for the quarter ended September 30, 2019. Consequently, the company obtained a waiver from its lender, Innovatus, subject to the following material changes:
- Warrant Price Reduction: As consideration for the revenue covenant waiver, the company agreed to amend a warrant issued to Innovatus, reducing the exercise price from $4.63 per share to $0.48 per share. This amendment must be completed by November 6, 2019.
- Liquidity Covenant Waiver: Innovatus waived non-compliance with the minimum cash balance covenant through October 31, 2019.
- Waiver Fee: A fee is due on November 1, 2019, contingent on equity financing:
- If the company raises at least $10 million in equity before October 31, 2019: 572,917 shares of Common Stock issued to Innovatus.
- If the equity financing is not completed: $250,000 in cash.
Outlook, Risks, and Management Commentary
Management notes that financial closing procedures for the quarter are incomplete, and final results may vary materially from the preliminary $3.3 million revenue estimate. The filing highlights significant liquidity risks, evidenced by the failure to meet cash balance covenants and the requirement to secure $10 million in equity financing to avoid a cash penalty and mitigate dilution.
Investor Verification Checklist
- Verify the final audited revenue for the quarter ended September 30, 2019, against the preliminary $3.3 million estimate.
- Confirm whether the company successfully raised $10 million in equity prior to October 31, 2019, to determine if the waiver fee will be paid in stock or cash.
- Monitor the execution of the warrant amendment to reduce the exercise price to $0.48 per share by the November 6, 2019 deadline.
- Assess the company's current cash position and runway given the recent liquidity covenant breach.